标题
Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch
作者
关键词
-
出版物
Frontiers in Oncology
Volume 4, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2014-04-10
DOI
10.3389/fonc.2014.00076
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
- (2015) Eddy Pasquier et al. Oncotarget
- Metronomics: towards personalized chemotherapy?
- (2014) Nicolas André et al. Nature Reviews Clinical Oncology
- β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
- (2013) E Pasquier et al. BRITISH JOURNAL OF CANCER
- A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs
- (2013) E. Guerin et al. CANCER RESEARCH
- Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer
- (2013) Erzsébet Juhász et al. EUROPEAN JOURNAL OF CANCER
- Low-dose metronomic chemotherapy: A systematic literature analysis
- (2013) K. Lien et al. EUROPEAN JOURNAL OF CANCER
- A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer
- (2013) A. Lange et al. EUROPEAN JOURNAL OF CANCER
- Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
- (2013) Marta Vives et al. INTERNATIONAL JOURNAL OF CANCER
- Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea
- (2013) David E. Gerber et al. JOURNAL OF CLINICAL ONCOLOGY
- The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
- (2013) Emma L. Barber et al. Journal of Gynecologic Oncology
- Has the time come for metronomics in low-income and middle-income countries?
- (2013) Nicolas André et al. LANCET ONCOLOGY
- Repositioning metformin for cancer prevention and treatment
- (2013) Brendan J. Quinn et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analyses
- (2012) YAN GAO et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer
- (2012) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Therapy for Advanced Non–Small-Cell Lung Cancer: A Pilot Study on Patients’ Perceptions
- (2012) Lies Peeters et al. Journal of Thoracic Oncology
- Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study
- (2012) Chandra P Belani et al. LANCET ONCOLOGY
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer
- (2011) B. T. Aftab et al. CANCER RESEARCH
- Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer
- (2011) Xinji Zhang et al. CHEST
- Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
- (2011) Nicholas J. Robert et al. Clinical Breast Cancer
- Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer
- (2011) Jamie L. Lesnock et al. GYNECOLOGIC ONCOLOGY
- Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2011) Alessandra Gennari et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma
- (2011) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy
- (2010) Angiolo Gadducci et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
- (2010) Robert Klein et al. Journal of Thoracic Oncology
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer
- (2010) William M. Merritt et al. MOLECULAR CANCER THERAPEUTICS
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1
- (2009) Sergio Pecorelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
- (2009) Howard Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- A change of strategy in the war on cancer
- (2009) Robert A. Gatenby NATURE
- Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors
- (2008) Alfonso Duenas-Gonzalez et al. CANCER TREATMENT REVIEWS
- Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
- (2008) Chandra P. Belani et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors
- (2007) L. Mi Rim Choi et al. PEDIATRIC BLOOD & CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now